The inodilator levosimendan as a treatment for acute heart failure in various settings

Finn Gustafsson; Fabio Guarracino; Robert H G Schwinger

doi:10.1093/eurheartj/sux001

The inodilator levosimendan as a treatment for acute heart failure in various settings

Finn Gustafsson, Fabio Guarracino, Robert H G Schwinger

11 Citationer (Scopus)

38 Downloads (Pure)

Abstract

Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.

Originalsprog	Engelsk
Tidsskrift	European Heart Journal Supplements
Vol/bind	19
Udgave nummer	Suppl C
Sider (fra-til)	C2-C7
Antal sider	6
ISSN	1554-2815
DOI	https://doi.org/10.1093/eurheartj/sux001
Status	Udgivet - 9 mar. 2017
Udgivet eksternt	Ja

Adgang til dokumentet

10.1093/eurheartj/sux001Licens: CC BY-NC

The inodilator levosimendan as a treatment for acute heart failure in various settingsForlagets udgivne version, 162 KBLicens: CC BY-NC

Citationsformater

@article{e007a6606c794b9090495ab2a531adc9,

title = "The inodilator levosimendan as a treatment for acute heart failure in various settings",

abstract = "Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.",

author = "Finn Gustafsson and Fabio Guarracino and Schwinger, {Robert H G}",

year = "2017",

month = mar,

day = "9",

doi = "10.1093/eurheartj/sux001",

language = "English",

volume = "19",

pages = "C2--C7",

journal = "European Heart Journal Supplements",

issn = "1554-2815",

publisher = "Oxford University Press",

number = "Suppl C",

}

TY - JOUR

T1 - The inodilator levosimendan as a treatment for acute heart failure in various settings

AU - Gustafsson, Finn

AU - Guarracino, Fabio

AU - Schwinger, Robert H G

PY - 2017/3/9

Y1 - 2017/3/9

N2 - Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.

AB - Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.

U2 - 10.1093/eurheartj/sux001

DO - 10.1093/eurheartj/sux001

M3 - Journal article

C2 - 29249904

SN - 1554-2815

VL - 19

SP - C2-C7

JO - European Heart Journal Supplements

JF - European Heart Journal Supplements

IS - Suppl C

ER -

The inodilator levosimendan as a treatment for acute heart failure in various settings

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater